Effect of Omalizumab Therapy on Coagulation Parameters and Total Immunoglobulin E Levels in Patients with Chronic Idiopathic Urticaria and Bullous Pemphigoid

• Published in: Türk dermatoloji dergisi 2018-12, Vol.12 (4), p.159-166
• Main Authors: İncel Uysal, Pınar, Hayran, Yıldız, Akdoğan, Neslihan, Öktem, Ayşe, Atılan, Ahmet, Gür Aksoy, Güneş, Yalçın, Başak
• Format: Article
• Language: English
• Subjects: Allergies; Asthma; Dermatitis; Dermatology; Family medical history; Immunoglobulins; Immunology; Immunotherapy; Medical records; Monoclonal antibodies; Pathogenesis; Studies; Thrombosis; Tıp; Urticaria
• ISSN: 1307-7635; 1308-5255
• DOI: 10.4274/tdd.3668

Objective: The aim of this study is to assess the impact of omalizumab on coagulation biomarkers and immunoglobulin E (IgE) levels in chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) and bullous pemphigoid (BP) patients. Methods: Medical records of 31 CIU/CSU and 16 BP patients were reviewed according to the inclusion and exclusion criteria. Laboratory parameters for coagulation status and IgE levels at baseline and in the first 12-week period of omalizumab therapy were retrieved and analysed in the light of clinical response to the treatment. Results: At baseline, in CIU/CSU patients, IgE levels were significantly higher in responders [184.5 IU/mL (62-307 IU/mL)] than non-responders [25.6 IU/mL (10.8-30.2 IU/mL)] (p=0.021). During the first 12 weeks of omalizumab therapy, a dramatic decrease in D-dimer levels was observed in serial measurements of CIU/CSU (p=0.001) and also BP patients (p=0.017). Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p